_id
6919ed7f3c536f8df231846d
Ticker
ROQ.LSE
Name
Roquefort Investments PLC
Exchange
LSE
Address
85 Great Portland Street, London, United Kingdom, W1W 7LT
Country
UK
Sector
Healthcare
Industry
Biotechnology
Currency
GBX
Website
https://www.roquefortplc.com
Description
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Last Close
14000
Volume
63330
Current Price
1.3
Change
-7.142857142857134
Last Updated
2025-12-30T11:27:53.418Z
Image
https://logo.clearbit.com/www.roquefortplc.com
Ipo Date
-
Market Cap
1964715
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
-
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
493408
Operating Income
-493408
Interest Expense
-
Pretax Income
-532034
Net Income
-490147
Eps
-0.003320329223682428
Dividends Per Share
-
Shares Outstanding
163726294
Income Tax Expense
41887
EBITDA
-490706
Operating Margin
-
Total Other Income Expense Net
-38626
Cash
182923
Short Term Investments
-
Receivables
31203
Inventories
-
Total Current Assets
1758019
Property Plant Equipment
42046
Total Assets
5662041
Payables
133687
Short Term Debt
383650
Long Term Debt
-
Total Liabilities
909121
Equity
4752920
Bs_currency_symbol
GBP
Depreciation
2702
Change In Working Capital
-11799
Cash From Operations
-329552
Capital Expenditures
56865
Cash From Investing
-56865
Cash From Financing
236000
Net Change In Cash
182923
Cf_currency_symbol
-
PE
-
PB
40.37644227127745
ROE
-10.312544709357615
ROA
-8.656719370276548
FCF
-386417
Fcf Percent
-
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
493408
Quarters > 0 > income Statement > operating Income
-493408
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-532034
Quarters > 0 > income Statement > net Income
-490147
Quarters > 0 > income Statement > eps
-0.003320329223682428
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
147620000
Quarters > 0 > income Statement > income Tax Expense
41887
Quarters > 0 > income Statement > EBITDA
-490706
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-38626
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
182923
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
31203
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
1758019
Quarters > 0 > balance Sheet > property Plant Equipment
42046
Quarters > 0 > balance Sheet > total Assets
5662041
Quarters > 0 > balance Sheet > payables
133687
Quarters > 0 > balance Sheet > short Term Debt
383650
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
909121
Quarters > 0 > balance Sheet > equity
4752920
Quarters > 0 > balance Sheet > currency_symbol
GBP
Quarters > 0 > cash Flow > net Income
-490147
Quarters > 0 > cash Flow > depreciation
2702
Quarters > 0 > cash Flow > change In Working Capital
-11799
Quarters > 0 > cash Flow > cash From Operations
-329552
Quarters > 0 > cash Flow > capital Expenditures
56865
Quarters > 0 > cash Flow > cash From Investing
-56865
Quarters > 0 > cash Flow > cash From Financing
236000
Quarters > 0 > cash Flow > net Change In Cash
182923
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.003320329223682428
Quarters > 0 > ratios > PB
40.37644227127745
Quarters > 0 > ratios > ROE
-10.312544709357615
Quarters > 0 > ratios > ROA
-8.656719370276548
Quarters > 0 > ratios > FCF
-386417
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
2702
Quarters > 1 > income Statement > gross Profit
-2702
Quarters > 1 > income Statement > operating Expenses
-678192
Quarters > 1 > income Statement > operating Income
-438727
Quarters > 1 > income Statement > interest Expense
72868
Quarters > 1 > income Statement > pretax Income
-511788
Quarters > 1 > income Statement > net Income
-392304
Quarters > 1 > income Statement > eps
-0.00299655231953356
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
130918455
Quarters > 1 > income Statement > income Tax Expense
119484
Quarters > 1 > income Statement > EBITDA
-436025
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-73061
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
337112
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
25380
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
362492
Quarters > 1 > balance Sheet > property Plant Equipment
44748
Quarters > 1 > balance Sheet > total Assets
5750745
Quarters > 1 > balance Sheet > payables
23033
Quarters > 1 > balance Sheet > short Term Debt
400092
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
861726
Quarters > 1 > balance Sheet > equity
4889019
Quarters > 1 > balance Sheet > currency_symbol
GBP
Quarters > 1 > cash Flow > net Income
-392304
Quarters > 1 > cash Flow > depreciation
2702
Quarters > 1 > cash Flow > change In Working Capital
60184
Quarters > 1 > cash Flow > cash From Operations
-259201
Quarters > 1 > cash Flow > capital Expenditures
4
Quarters > 1 > cash Flow > cash From Investing
-193
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-258550
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.00299655231953356
Quarters > 1 > ratios > PB
34.811480892178984
Quarters > 1 > ratios > ROE
-8.02418644721978
Quarters > 1 > ratios > ROA
-6.821794393595961
Quarters > 1 > ratios > FCF
-259205
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
2702
Quarters > 2 > income Statement > cost Of Revenue
18702
Quarters > 2 > income Statement > gross Profit
-16000
Quarters > 2 > income Statement > operating Expenses
662192
Quarters > 2 > income Statement > operating Income
-678192
Quarters > 2 > income Statement > interest Expense
24782
Quarters > 2 > income Statement > pretax Income
-702782
Quarters > 2 > income Statement > net Income
-579500
Quarters > 2 > income Statement > eps
-0.00448703065407713
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
129149998
Quarters > 2 > income Statement > income Tax Expense
123282
Quarters > 2 > income Statement > EBITDA
-675490
Quarters > 2 > income Statement > operating Margin
-25099.62990377498
Quarters > 2 > income Statement > total Other Income Expense Net
-24590
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
595662
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
87361
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
683023
Quarters > 2 > balance Sheet > property Plant Equipment
47450
Quarters > 2 > balance Sheet > total Assets
6073978
Quarters > 2 > balance Sheet > payables
135631
Quarters > 2 > balance Sheet > short Term Debt
609697
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
1144666
Quarters > 2 > balance Sheet > equity
4929312
Quarters > 2 > balance Sheet > currency_symbol
GBP
Quarters > 2 > cash Flow > net Income
-579499
Quarters > 2 > cash Flow > depreciation
2702
Quarters > 2 > cash Flow > change In Working Capital
70228
Quarters > 2 > cash Flow > cash From Operations
-524530
Quarters > 2 > cash Flow > capital Expenditures
3
Quarters > 2 > cash Flow > cash From Investing
194
Quarters > 2 > cash Flow > cash From Financing
584916
Quarters > 2 > cash Flow > net Change In Cash
58340
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.00448703065407713
Quarters > 2 > ratios > PB
34.06053368096806
Quarters > 2 > ratios > ROE
-11.756204516979246
Quarters > 2 > ratios > ROA
-9.540699686432845
Quarters > 2 > ratios > FCF
-524533
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-194.12768319763137
Quarters > 2 > health Score
27
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
8000
Quarters > 3 > income Statement > gross Profit
-8000
Quarters > 3 > income Statement > operating Expenses
331096
Quarters > 3 > income Statement > operating Income
-339096
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-351391
Quarters > 3 > income Statement > net Income
-289750
Quarters > 3 > income Statement > eps
-0.002243515327038565
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
129149998
Quarters > 3 > income Statement > income Tax Expense
61641
Quarters > 3 > income Statement > EBITDA
-337745
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-12295
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
595662
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
87361
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
683023
Quarters > 3 > balance Sheet > property Plant Equipment
47450
Quarters > 3 > balance Sheet > total Assets
6073978
Quarters > 3 > balance Sheet > payables
135631
Quarters > 3 > balance Sheet > short Term Debt
609697
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
1144666
Quarters > 3 > balance Sheet > equity
4929312
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-289750
Quarters > 3 > cash Flow > depreciation
1351
Quarters > 3 > cash Flow > change In Working Capital
35114
Quarters > 3 > cash Flow > cash From Operations
-262265
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
292458
Quarters > 3 > cash Flow > net Change In Cash
29171
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.002243515327038565
Quarters > 3 > ratios > PB
34.06053368096806
Quarters > 3 > ratios > ROE
-5.878102258489623
Quarters > 3 > ratios > ROA
-4.770349843216422
Quarters > 3 > ratios > FCF
-262265
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
16000
Annuals > 0 > income Statement > gross Profit
-16000
Annuals > 0 > income Statement > operating Expenses
1095515
Annuals > 0 > income Statement > operating Income
-1111515
Annuals > 0 > income Statement > interest Expense
97650
Annuals > 0 > income Statement > pretax Income
-1214569
Annuals > 0 > income Statement > net Income
-971803
Annuals > 0 > income Statement > eps
-0.0074734401079912605
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
130034226
Annuals > 0 > income Statement > income Tax Expense
242766
Annuals > 0 > income Statement > EBITDA
-1111515
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-103054
Annuals > 0 > income Statement > currency_symbol
GBP
Annuals > 0 > balance Sheet > cash
337112
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
25380
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
362492
Annuals > 0 > balance Sheet > property Plant Equipment
44748
Annuals > 0 > balance Sheet > total Assets
5750745
Annuals > 0 > balance Sheet > payables
23033
Annuals > 0 > balance Sheet > short Term Debt
400092
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
861726
Annuals > 0 > balance Sheet > equity
4889019
Annuals > 0 > balance Sheet > currency_symbol
GBP
Annuals > 0 > cash Flow > net Income
-1214569
Annuals > 0 > cash Flow > depreciation
5404
Annuals > 0 > cash Flow > change In Working Capital
9269
Annuals > 0 > cash Flow > cash From Operations
-783731
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
584915
Annuals > 0 > cash Flow > net Change In Cash
-200210
Annuals > 0 > cash Flow > currency_symbol
GBP
Annuals > 0 > ratios > PE
-0.0074734401079912605
Annuals > 0 > ratios > PB
31.91664241844836
Annuals > 0 > ratios > ROE
-19.877259630203934
Annuals > 0 > ratios > ROA
-16.89873225121267
Annuals > 0 > ratios > FCF
-783731
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
200000
Annuals > 1 > income Statement > cost Of Revenue
3890
Annuals > 1 > income Statement > gross Profit
200000
Annuals > 1 > income Statement > operating Expenses
2129754
Annuals > 1 > income Statement > operating Income
-1933644
Annuals > 1 > income Statement > interest Expense
58
Annuals > 1 > income Statement > pretax Income
-1932233
Annuals > 1 > income Statement > net Income
-1744540
Annuals > 1 > income Statement > eps
-0.013507859287771727
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
129149998
Annuals > 1 > income Statement > income Tax Expense
-187693
Annuals > 1 > income Statement > EBITDA
-1928345
Annuals > 1 > income Statement > operating Margin
-966.822
Annuals > 1 > income Statement > total Other Income Expense Net
1411
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
537322
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
157589
Annuals > 1 > balance Sheet > inventories
-157588
Annuals > 1 > balance Sheet > total Current Assets
694911
Annuals > 1 > balance Sheet > property Plant Equipment
50152
Annuals > 1 > balance Sheet > total Assets
6088568
Annuals > 1 > balance Sheet > payables
144841
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
589025
Annuals > 1 > balance Sheet > equity
5499543
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-1744540
Annuals > 1 > cash Flow > depreciation
3890
Annuals > 1 > cash Flow > change In Working Capital
-28407
Annuals > 1 > cash Flow > cash From Operations
-1733533
Annuals > 1 > cash Flow > capital Expenditures
54042
Annuals > 1 > cash Flow > cash From Investing
-52573
Annuals > 1 > cash Flow > cash From Financing
-58
Annuals > 1 > cash Flow > net Change In Cash
-1785652
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-0.013507859287771727
Annuals > 1 > ratios > PB
28.18052292708685
Annuals > 1 > ratios > ROE
-31.721544862909518
Annuals > 1 > ratios > ROA
-28.652714398525237
Annuals > 1 > ratios > FCF
-1787575
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-8.937875
Annuals > 1 > health Score
26
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
0
Annuals > 2 > income Statement > gross Profit
0
Annuals > 2 > income Statement > operating Expenses
1634301
Annuals > 2 > income Statement > operating Income
-1634303
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-1634303
Annuals > 2 > income Statement > net Income
-1615417
Annuals > 2 > income Statement > eps
-0.015610989371457582
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
103479476
Annuals > 2 > income Statement > income Tax Expense
-18886
Annuals > 2 > income Statement > EBITDA
-1634301
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-3
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
2322974
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
101738
Annuals > 2 > balance Sheet > inventories
-101738
Annuals > 2 > balance Sheet > total Current Assets
2424712
Annuals > 2 > balance Sheet > property Plant Equipment
0
Annuals > 2 > balance Sheet > total Assets
7768217
Annuals > 2 > balance Sheet > payables
68379
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
561581
Annuals > 2 > balance Sheet > equity
7206636
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-1634303
Annuals > 2 > cash Flow > depreciation
0
Annuals > 2 > cash Flow > change In Working Capital
39432
Annuals > 2 > cash Flow > cash From Operations
-1577476
Annuals > 2 > cash Flow > capital Expenditures
4
Annuals > 2 > cash Flow > cash From Investing
-103478
Annuals > 2 > cash Flow > cash From Financing
3102212
Annuals > 2 > cash Flow > net Change In Cash
1423253
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-0.015610989371457582
Annuals > 2 > ratios > PB
17.23069837299955
Annuals > 2 > ratios > ROE
-22.415687430307287
Annuals > 2 > ratios > ROA
-20.7952095056047
Annuals > 2 > ratios > FCF
-1577480
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
26
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
719
Annuals > 3 > income Statement > cost Of Revenue
10069
Annuals > 3 > income Statement > gross Profit
-9350
Annuals > 3 > income Statement > operating Expenses
501416
Annuals > 3 > income Statement > operating Income
-510769
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-917433
Annuals > 3 > income Statement > net Income
-917433
Annuals > 3 > income Statement > eps
-0.037140340379340074
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
24701793
Annuals > 3 > income Statement > income Tax Expense
-200923
Annuals > 3 > income Statement > EBITDA
-352403
Annuals > 3 > income Statement > operating Margin
-71038.80389429763
Annuals > 3 > income Statement > total Other Income Expense Net
-406667
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
899721
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
2178783
Annuals > 3 > balance Sheet > inventories
-2160958
Annuals > 3 > balance Sheet > total Current Assets
3078504
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
4560034
Annuals > 3 > balance Sheet > payables
40718
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
477428
Annuals > 3 > balance Sheet > equity
4082606
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-917433
Annuals > 3 > cash Flow > depreciation
382977
Annuals > 3 > cash Flow > change In Working Capital
-1991838
Annuals > 3 > cash Flow > cash From Operations
-2623035
Annuals > 3 > cash Flow > capital Expenditures
5
Annuals > 3 > cash Flow > cash From Investing
-1106225
Annuals > 3 > cash Flow > cash From Financing
4629595
Annuals > 3 > cash Flow > net Change In Cash
899874
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-0.037140340379340074
Annuals > 3 > ratios > PB
7.260595707741575
Annuals > 3 > ratios > ROE
-22.471749661858137
Annuals > 3 > ratios > ROA
-20.118994726793705
Annuals > 3 > ratios > FCF
-2623040
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-3648.1780250347706
Annuals > 3 > health Score
26
Valuation > metrics > PE
-0.003320329223682428
Valuation > metrics > PB
40.37644227127745
Valuation > final Score
20
Valuation > verdict
1245.9% Overvalued
Profitability > metrics > ROE
-10.312544709357615
Profitability > metrics > ROA
-27.880642928204985
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.19127631014197588
Risk > metrics > Interest Coverage
-11.938830816879598
Risk > final Score
12
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.398208517852
Liquidity > metrics > Quick Ratio
3.398208517852
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
0
Prev Profitabilities > 2
15
Prev Risks > 0
36
Prev Risks > 1
-49
Prev Risks > 2
-39
Prev Liquidities > 0
53
Prev Liquidities > 1
56
Prev Liquidities > 2
56
Updated At
2026-01-20T23:03:40.336Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-28
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-09-30
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-04-30
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
0
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-06-30
Earnings History > 3 > report Date
2024-09-27
Earnings History > 3 > date
2024-06-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Stock Price
GBp 0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AFTSE 100 Live: London stocks fall as cannabis news hits tobacco giants, US tech slumps Proactive financial news
Read more →Roquefort Therapeutics shares marked ex-entitlement for unlisted shares Investing.com
Read more →Showing 2 of 6
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Roquefort Investments PLC
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2026-03-31
EPS Estimate
—
Date
2025-06-30
EPS Actual
0
EPS Estimate
0
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2025-06-30)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.